Geron Corp (GERN) Stock Price, Quote & News

Company Profile

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractor...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 473 7700

Website: www.geron.com

Address:

919 East Hillsdale Boulevard, Suite 250, Foster City, United States

ZoeyTanner Aug. 16 at 2:55 PM

$GERN So many bios have left Geron in rear view mirror. SLS & IOVA come to mind, if only we had taken a different path. 2026 is doom or riches

0 · Reply

Kazarius Aug. 16 at 9:17 AM

$GERN Renaissance Technologies increased its GERN position by 154%. It now reports approximately: 4.579 million GERN shares versus roughly: 1.80 million shares previously.

1 · Reply

ZoeyTanner Aug. 15 at 3:31 PM

$GERN Geron 13G : RA Capital reducing share numbers..listing two agents. There is always someone tired of this. The financial pain is too much. Can there really be 'old timers' still around and bruised but breathing?

3 · Reply

Huntlardo Aug. 15 at 11:45 AM

$GERN we didnt want a break out on low volume that wont sustainable. keep on trying to break it up.

0 · Reply

Huntlardo Aug. 15 at 11:44 AM

$GERN RA capital topping off their position to 9.9% filed 13G friday

0 · Reply

stanky_dank27 Aug. 15 at 4:33 AM

$GERN strange that Goldman would be increasing their position, by the millions, on a company that was 30-60 % over their analyst’s price target for most of the quarter.

1 · Reply

Samsquantch Aug. 14 at 4:56 PM

$GERN Rinse and repeat, I'll load up again in the low 20's.

3 · Reply

Mpgmd Aug. 14 at 4:55 PM

$GERN I was afraid this would happen when I saw bullish readings in the low to high 80’s earlier this week. Never fails unfortunately

0 · Reply

BubblesMcGee123 Aug. 14 at 4:51 PM

$GERN According to Perplexity, this is what's happened since Geron's August 5th earnings report: "Wedbush reiterated its Buy rating on August 5 with a $6.00 target. TD Cowen also issued a Buy recommendation around the results, though the available report does not disclose a target change. H.C. Wainwright maintained a Hold rating and cut its 2026 EPS forecast to a $0.05 loss from a $0.02 loss, but the source does not report a price-target revision. So, I would not treat this as confirmation that any biotech analyst raised or cut a price target after August 5. The clearest reported target was Wedbush’s unchanged $6.00, and overall published consensus was about $4.00"

0 · Reply

ZoeyTanner Aug. 14 at 4:28 PM

$GERN It is looking like the investor do not believe IDMC will come clean on interim results. More and more finding an exit strategy.

2 · Reply

Geron Earnings Call Transcript: Q2 2026

Aug 5, 2026, 8:00 AM EDT - 11 days ago

Geron Earnings release: Q2 2026

Aug 5, 2026, 8:00 AM EDT - 11 days ago

Geron Quarterly report: Q2 2026

2026-08-05T11:50:46.000Z - 11 days ago

Market Cap	944.44M
Revenue (ttm)	183.88M
Net Income (ttm)	-83.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-45.41%
Debt to Equity Ratio	0.55

Volume	11,157,899
Avg Vol	12,351,410
Day's Range	N/A - N/A
Shares Out	642.47M
Stochastic %K	47%
Beta	0.61
Analysts	Sell
Price Target	$3.60